GENEURO SA (GNRO.PA) Stock Price, Forecast & Analysis

EPA:GNRO • CH0308403085

0.0308 EUR
0 (-0.65%)
Last: Jan 22, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership

GNRO.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap916.61K
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares29.76M
Float14.97M
52 Week High0.24
52 Week Low0.02
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2016-04-15
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
GNRO.PA short term performance overview.The bars show the price performance of GNRO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 -15

GNRO.PA long term performance overview.The bars show the price performance of GNRO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GNRO.PA is 0.0308 EUR. In the past month the price increased by 2.67%. In the past year, price decreased by -81.05%.

GENEURO SA / GNRO Daily stock chart

GNRO.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to GNRO.PA. When comparing the yearly performance of all stocks, GNRO.PA is a bad performer in the overall market: 97.34% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
GNRO.PA Full Technical Analysis Report

GNRO.PA Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
GNRO.PA financials

GNRO.PA Forecast & Estimates


Analysts
Analysts85.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
GNRO.PA Analyst EstimatesGNRO.PA Analyst Ratings

GNRO.PA Ownership

Ownership
Inst Owners11.96%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
GNRO.PA Ownership

GNRO.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ARGX ARGENX SE28.6544.21B
1AE ARGENX SE28.1944.16B
22UA BIONTECH SE-ADR N/A22.038B
ABVX ABIVAX SA N/A8.73B
2X1 ABIVAX SA N/A8.73B
GLPG GALAPAGOS NV N/A1.911B
GXE GALAPAGOS NV N/A1.911B
IVA INVENTIVA SA N/A1.108B
NANO NANOBIOTIX N/A1.106B
6IV INVENTIVA SA N/A1.075B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About GNRO.PA

Company Profile

GNRO logo image GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Company Info

GENEURO SA

3, Chemin du Pre-Fleuri

Plan-les-Ouates GENEVE CH

Employees: 17

GNRO Company Website

GNRO Investor Relations

Phone: 41225524800

GENEURO SA / GNRO.PA FAQ

What does GNRO do?

GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.


What is the current price of GNRO stock?

The current stock price of GNRO.PA is 0.0308 EUR. The price decreased by -0.65% in the last trading session.


Does GENEURO SA pay dividends?

GNRO.PA does not pay a dividend.


What is the ChartMill rating of GENEURO SA stock?

GNRO.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What sector and industry does GENEURO SA belong to?

GENEURO SA (GNRO.PA) operates in the Health Care sector and the Biotechnology industry.


Who owns GENEURO SA?

You can find the ownership structure of GENEURO SA (GNRO.PA) on the Ownership tab.